11:52 AM EST - Paladin Labs Inc : announced today that Health Canada has approved Oralair™. Oralair™ is a sublingual grass pollen immunotherapy tablet for the treatment of the symptoms of moderate to severe seasonal grass pollen allergic rhinitis with or without conjunctivitis. Paladin Labs Inc
shares T.PLB are trading down $0.07 at $39.43.
